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Abstract
This research aims to establish the prevalence and aetiology of anxiety and depression in cancer patients
within their first 2 weeks of a radical course of radiotherapy. Depression followed by anxiety is the two
most frequent psychological disorders experienced by cancer patients. However, these two disorders are
frequently undiagnosed and untreated in patients undergoing a course of radiotherapy possibly because
the treatment side effects often simulate those of anxiety and depression; the consequences of this can
be reduced patient prognosis and increased health care costs. A questionnaire was administered to a
sample of 100 eligible cancer patients and this yielded a 68% response rate. The Hospital Anxiety and
Depression (HAD) scale was integrated into the questionnaire to accurately establish levels of anxiety and
depression in the respondents of the study. The study identified six respondents with clinically sig-
nificant levels of anxiety (9%) and six with depression (9%); 21% (n ¼ 14) of participants had higher
than normal levels of anxiety and 21% for depression (n ¼ 14). Correlations were then identified between
levels of psychological distress and the four independent variables; age, diagnosis, adjuvant medication
and pain. Four predisposing factors were established—breast cancer diagnosis, age range 4050 years,
the presence of pain and adjuvant chemotherapy regimes.
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INTRODUCTION
Cancer is a powerful word which can inflict a
whole range of emotions upon someone diag-
nosed with it. Unfortunately, recent statistics sug-
gest that as many as one in three people will be
diagnosed with cancer in his/her lifetime1, with
the incidence thought to be increasing. Approxi-
mately 50% of these people will undergo radiation
treatment for the disease.2
A diagnosis of cancer brings with it incredible
loss of personal identity and bodily integrity.3
There is also the fear and anxiety that comes
with the unknown. Furthermore, cancer is greatly
associated with mortality,4 the incidence of
which is said to be one in four of those affected.1
Unfortunately, this emotional turmoil is common
and an expected reaction to cancer diagnosis.
The two most reported emotions associated with
a cancer diagnosis are depression, followed by
anxiety.5 Thus, the diagnosis and management of
these two psychiatric disorders needs to be
addressed.
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BACKGROUND
Anxiety and depression
According to the Online Medical Dictionary,6
anxiety is defined as:
The unpleasant emotional state consisting
of psychophysiology responses to anticipa-
tion of unreal or imagined danger, ostensi-
bly resulting from intrapsychic conflict.
Psychological concomitants include feel-
ings of impending danger, powerlessness,
apprehension and tension.
To distinguish between these two terms,
depression can be described as:
A mental state of depressed mood charac-
terised by feelings of sadness, despair and
discouragement. There are often feelings
of low self esteem, guilt and self reproach,
withdrawal from interpersonal contact
and somatic problems such as eating and
sleep disturbances.
Absolute definitions of mental illness cannot
be made as they are subject to interpretation7
relative to individual cultural contexts. Never-
theless, these two definitions manage to encom-
pass the main aspects of the two psychological
disorders.
The exact incidence of anxiety and depres-
sion in cancer populations is inconsistent and
reportedly ranges from 0 to 49% in literature.8,9
Furthermore, it has been proposed that as much
as 80% of psychiatric disorders go undetected
and subsequently remain untreated.10 This fig-
ure highlights the importance and need for the
development and utilisation of psychosocial
screening programmes in radiotherapy, an area
historically neglected by researchers.
The implications of anxiety and
depression remaining undiagnosed
Depression is potentially a co-morbid, disabling
syndrome,11 which can impede a cancer patient’s
prognosis and functional status and may lead to
poor adherence to treatment recommenda-
tions.12 Studies have demonstrated a reduced
prognosis in women with breast cancer, support-
ing the need for further identification and
study.12 Furthermore, depression is an expensive
psychopathology and when combined with
medical illness, health care costs are elevated as a
result of longer hospital stays which incur mone-
tary expense.13
METHODOLOGY
Research design
This study can be described as a non-randomised,
cross-sectional survey of 100 eligible cancer
patients—within their first 2 weeks of a radical
course of radiotherapy—over the age of 18 years
and with an outpatient status. A questionnaire
was used to identify how the independent
variables (age, diagnosis, levels of pain and adju-
vant medication) correlated with the dependant
variables (anxiety and depression) in an attempt
to support or refute current literature. A conve-
nience sample was used to expedite collection
of data. Although this sampling method is non-
probability, suggesting less representative data
and even possible bias, it was deemed to be the
most feasible and practical method with regard
to time constraints.
Questionnaire
Section A: patient demographics
Section ‘A’ of the questionnaire aimed to gather
personal, demographic data from each respon-
dent. It contained a mixture of both open- and
closed-type questions, a format frequently used
by researchers to obtain both quantitative and
qualitative data which is suggested to increase
the validity of a study.14 Three of the indepen-
dent variables—age, adjuvant medication and
diagnosis, were chosen to establish continuity as
current findings prove to be inconsistent in these
areas of research. The fourth independent vari-
able, pain had been studied explicitly and a strong
positive correlation between this and psychologi-
cal dysfunction was well documented.15 There-
fore, a correlation was expected between pain
and psychological status to be able to maintain
some level of validity and reliability within this
study. It is acknowledged by the researcher that
the response to this question is subjective
and relies heavily on personal interpretation of
pain. Consequently, only four set answers were
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available to be able to provide some structure to
the response and caution was applied when inter-
preting the research findings.
Section B: the hospital anxiety and depression
(HAD) scale
Section ‘B’ of the questionnaire contained the
well-established HAD scale, which consists of
a series of 14 multiple choice questions, where
the patient is asked to circle one of the four
set answers that best describes how they are
feeling. There is a maximum score of 21 for
each psychological state. The scale is composed
of two sub-sections: one which measures anxi-
ety, and the other depression. A score of > 11
on either sub-section indicates significant levels
of anxiety and/or depression, which is when
psychological intervention may be necessary.
This cut-off point has been traditionally used
in literature to achieve a sensitivity of 7095%
for identifying a case of anxiety disorder or
depression.16 This screening tool is quick
and easy to complete in this format and is self-
explanatory which was thought to raise the
appeal of the questionnaire and hence increase
response rate. The scale also generates numeri-
cal data to facilitate data analysis.
However, the results of the pilot study
revealed that one participant felt the options in
the HAD scale were inconsistent and assumed
some level of anxiety and depression, which
may not be present. This was seen as a fault of
the scale, and manipulation of it could jeopar-
dise the validity of the psychometric screening
tool, so this point unfortunately could not be
addressed but was certainly accounted for dur-
ing data analysis.
Patient anonymity
The researcher made a list of the first 100
patients who adhered to the eligibility criteria.
Their names where then securely stored in a
log book and each questionnaire coded to pre-
serve patient anonymity. All one hundred
potential participants were approached by the
researcher and encouraged to take the informa-
tion home to read to fully understand the
implications of the study. All completed ques-
tionnaires and consent forms were returned to
a collection box placed in the waiting room of
each radiotherapy treatment machine within 5
days. During data analysis, if the researcher
identified any score above 11 on either sub-
section of the HAD scale, the code on the
questionnaire was used to reveal the patient’s
identity and clinical oncologist (both stored in
the log book). The researcher personally dis-
closed the patient’s name and score to the
consultant clinical oncologist and relevant mem-
bers of the team. Thus, the patient’s data was no
longer anonymous. All patients had agreed to
this disclosure when signing the consent form
and it was verbally reiterated when the potential
participants were introduced to the researcher.
Ethical considerations
Approval from the Local Research and Ethics
Committee (LREC) as well as the Hospital
Research and Development Committee (R&D)
has to be sought before conducting any study on
patients in the hospital setting.Written permission
was also required from the head of department,
and the consultant clinical oncologists also had to
sign to consent to their patient’s participation in
the research as they are responsible for their safety
and welfare.
RESULTS
The Statistical Package for Social Sciences
(SPSS) was utilised to analyse the data. The
study identified six respondents with clinically
significant levels of anxiety (9%) and six with
depression (9%) (Table 1). However, it is
important to acknowledge all patients with
raised levels of anxiety and depression, even
those whose symptoms are not clinically signif-
icant.17 Subsequently, the incidence of anxiety
considered to exceed normal levels has been
identified as 21% (n ¼ 14) for anxiety and
21% for depression (n ¼ 14). The large majority
Table 1. Summary of the incidence of anxiety and depression
Normal
(07)
Mild-moderate
(810)
Clinically significant
(11þ)
Anxiety 79%
(n ¼ 54)
12%
(n ¼ 8)
9%
(n ¼ 6)
Depression 79%
(n ¼ 54)
12%
(n ¼ 8)
9%
(n ¼ 6)
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of respondents (79%, n ¼ 54) expressed levels of
anxiety and depression that were considered
normal.
Figure 1 displays a linear correlation between
anxiety and the independent variable: pain and
a less linear but still positive correlation between
pain and depression. Differences between the
two can be observed; anxiety levels display a
steady exponential increase and are greater
than depression in the participants of this study.
Depression only follows this linear trend until
the pain becomes mild, without the need for
painkillers, it then proceeds to increase at a
slower rate.
One tailed Spearman’s Rank Correlation
Coefficient tests were performed to establish the
statistical significance of the correlation between
pain and anxiety and depression. The results sug-
gest that the relationship between pain and anxiety
is statistically significant (r ¼ 0.406, p ¼ 0.000).
For the results to be statistically significant to a
99% confidence interval, the p value should be
<0.01 and the minimum r value for this sample
size is 0.2782 at the levels of 0.01 to be signifi-
cant.18 The correlation between depression
and pain is also statistically significant (r ¼ 0.357,
p ¼ 0.001) to the level of 0.01, giving a 99% con-
fidence interval that the results were not due to
chance.
The majority of respondents [n¼ 38 (56%)] are
experiencing no pain, as illustrated in Figure 2.
There was also the option to describe the pain as
‘severe, continual/long lasting’. However, none
of the respondents selected this option so it has
been omitted from analysis.
Figure 3 looks at the effect that adjuvant med-
ication has on mean levels of anxiety and depres-
sion within the sample population. The bar graph
shows that, overall, anxiety and depression levels
are greater in respondents taking adjuvant medi-
cation. The graph represents a rapid mean
increase in levels of anxiety after the administra-
tion of chemotherapy agents. Levels of depres-
sion were less affected. From the graph, it can
be assumed that anxiety levels are generally
greater than depression levels. The exception is
respondents undergoing chemotherapy regimes
who appear to be slightly more depressed than
anxious.
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Figure 1. Positive correlation between pain and anxiety and
depression.
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Figure 2. The amount of pain experienced by the respondents.
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Most of the respondents (n ¼ 27; 40%) were
receiving no adjuvant medication. n ¼ 18 parti-
cipants (27%) did not receive any other medica-
tion. n ¼ 9 (13%) respondents were undergoing
various adjuvant chemotherapy regimes. n ¼ 8
(12%) respondents have adjuvant tamoxifen
intervention and n ¼ 6 (9%) respondents were
undergoing adjuvant zoladex injections.
It can be seen in Table 2 that most respon-
dents experience normal levels of anxiety and
depression, regardless of their age. The excep-
tions are patients in the 4050 year age range
and respondents aged 1828. Mild to moderate
levels were seen in these age ranges and
clinically significant levels of depression were
identified in the 1828 age range.
Figure 4 illustrates that the respondents with
cancer of the head and neck suffer the greatest
amount of anxiety and depression. Once again,
respondents can be identified as suffering from
more anxiety than depression; the only excep-
tion is head and neck respondents. However,
Figure 5 below shows the different sample sizes
for each diagnosis. As there were only four
respondents with cancers of the bone and oeso-
phagus, these two diagnoses were omitted from
analysis.
DISCUSSION
The three diagnoses found to exhibit clinically
significant levels of anxiety and depression, all
shared two common predisposing characteristics;
they all reportedly suffered the greatest amounts
of pain, concurring with previous literature.15
They also each contained patients currently
undergoing adjuvant chemotherapy regimes,
supporting Yarbro19 who proposed that concur-
rent therapy exacerbates treatment toxicity and
subsequent psychological morbidity.
Pain
Pain can be debilitating, limiting normal func-
tioning and subsequently hindering quality of
life.15,20 Subsequently, pain has been frequently
linked to depression in literature,2022 but
interestingly, the effect of pain on levels of anxi-
ety is not documented. On the contrary, pain
was found to have a stronger correlation with
anxiety than depression in this current research.
This may be a consequence of the subjectivity
of self-reported pain,23 in addition to overall
heightened levels of anxiety exhibited by the
participants of this study. Nevertheless, the cor-
relation between anxiety, depression and pain
was found to be statistically significant in this
research.
Cervical participants
The other group of respondents seen to exhibit
significant levels of anxiety and depression were
cervical patients. These findings of this study are
consistent with reports that gynaecological
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Figure 3. The effect of adjuvant medication on psychological
distress.
Table 2. Relationship between age and mean levels of anxiety and
depression
Age Range
(years)
Anxiety
(mean)
Depression
(mean)
n
1828 Mild-Moderate Clinically Significant 1
2939 Normal Normal 4
4050 Mild-Moderate Mild-Moderate 13
5161 Normal Normal 20
6272 Normal Normal 26
7383 Normal Normal 3
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patients suffer more modest, but still significant,
levels of anxiety and depression.24 The one cer-
vical patient who was identified as clinically
anxious and depressed was in the age range of
1828 years, concurring with Hann et al.’s25
findings. It seems likely that younger cervical
patients may suffer greater levels of psychologi-
cal distress than those of an older age range as
radiotherapy side effects such as infertility and
inability to fulfil sexual relationships may be
more relevant to them. However, the small
sample size means caution must be applied
when interpreting this finding as the sample
could quite possibly be unrepresentative, giving
an anomalous result.
Head and neck participants
In this study, head and neck patients were
found to suffer the greatest mean levels of anxi-
ety and depression than any other diagnosis.
This finding supports previous research into
this psychological area which links higher levels
of anxiety and depression to patients with can-
cer of the head and neck.26
The physical side effects of radiotherapy in
patients with cancer of the head and neck
(xerostomia, dysphagia, mucositis and adverse
pain)27 can be disabling and a great hindrance
to quality of life. With the addition of concur-
rent chemotherapy, treatment toxicity is
enhanced and patients are most at risk of devel-
oping psychological illness.27,28 However, only
one head and neck patient underwent adjuvant
chemotherapy intervention in this research, so
this study is unlikely to display a true reflection
of this effect.
Depression and anxiety were both raised in
the head and neck respondents of this research;
however, depression appeared more potent
and prevailed. The reliability of the finding is
maintained by Anderson and Franke29 who
propose that patients with cancer of the head
and neck are more prone to depression than
any other psychiatric disorder. It has been sug-
gested that the majority of these patients are
likely to have a history of excessive tobacco
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Figure 4. The effect of diagnosis on psychological distress.
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Figure 5. Bar graph showing respondents by diagnosis.
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and alcohol consumption and may feel guilty
for their health risk behaviours.30 Levels of
depression were only just found to exceed
anxiety for this group of patients in this
research so the reliability of this finding is
uncertain. Caution should be applied especially
as the sample consisted of only six head and
neck respondents. This limitation may also be
responsible for the low incidence of clinically
significant levels of anxiety and depression
(n ¼ 1) detected in this study. However, the
one head and neck patient identified with
clinically significant symptoms reported the
highest levels of anxiety and depression in the
whole study, scoring 19 for anxiety and 17
for depression. This may be an anomalous
result as the lack of control over extraneous
variables means their influence cannot be
undermined. Nevertheless, this finding cannot
be disregarded as there is always the possibility
that it is valid.
Breast participants
Sixty-seven percent (n ¼ 8/12) of respondents
identified as exhibiting clinically significant
levels of anxiety and depression were breast
patients, supporting findings from current
research.31
Even though tamoxifen is renowned for its
numerous hormonal side effects which can
induce menopausal symptoms such as depres-
sion32 the use of tamoxifen did not appear to
increase mean levels of depression in the breast
cancer patients sampled, when compared to
those taking other medication. This concurred
with findings from a much larger nationwide
study which found no distinct difference in
levels of anxiety or depression between the
experimental group (those administered tamox-
ifen) and the control group (those administered
a placebo drug).33 However, anxiety levels did
appear to be heightened. Overall, only 26%
(n ¼ 8/31) of patients with breast cancer were
taking adjuvant medication, subsequently, other
predisposing factors must have been present to
heighten levels of psychological distress in the
breast cancer respondents. The psychological
impact of surgical disfigurement cannot be
underestimated in breast cancer patients.34 The
subsequent feelings of loss of femininity, shame
and embarrassment can induce depressive and
anxious symptoms. However, this could not
be determined by this research.
The six (19%) patients with breast cancer
who were also undergoing adjuvant che-
motherapy treatment were found to be more
anxious and depressed than those undergoing
any other adjuvant medication. Once again,
the onset of psychological distress has been
attributed to the side effects of chemotherapy—
alopecia, fatigue, nausea and vomiting and loss
of libido can undoubtedly hinder quality of
life.35
Prostate patients
Interestingly, prostate patients were found to be
least at risk of developing abnormal levels of
anxiety and depression, which can be attributed
to the patient characteristics of this population
of cancer patients. They are all male, 76%
(n ¼ 13) are aged between 62 and 72 years
and 82% (n ¼ 14) are experiencing no pain;
hence, the majority of this sample were not
exposed to any previously identified predispos-
ing characteristics of psychological distress.
Older prostate patients are less likely to suffer
psychological disturbances than their younger
counterparts.36 This has been attributed to the
greater amounts of social support available to
older patients.37 However, the effect of social
support cannot be established by this study as
the researcher felt that the different aspects of
this variable make it too complicated and sub-
jective to be able to justify its inclusion.
Gender
Eighty-three percent (10/12) of the patients
identified as being clinically anxious and/or
depressed were females. Even though gender
was not one of the independent variables
which the researcher chose to study, it could
not be ignored as its influence on levels of
anxiety and depression appeared significant in
this research. The exact cause of the gender
divide is uncertain in literature although hor-
monal imbalances as well as women’s willing-
ness to express emotions has been suggested,38
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making them more open to psychiatric identi-
fication.
Validity and reliability
The data from this current study is obtained
from cancer patients within their first 2 weeks
of radiotherapy, before the onset of physical
radiation side effects, a potential precursor of
psychological dysfunction.39 Thus, the cross-
sectional design limits the generalisability of
the results to only those patients who are within
their first few weeks of radiation treatment. It
may also suggest that these results only modestly
reflect the suffering of patients at later stages.
On the contrary it has been suggested that anxi-
ety levels may be at their greatest at this early
stage,40 offering a possible explanation for why
anxiety levels tend to exceed depression in the
results of this cross-sectional survey.
As predicted, convenience sampling was a
limiting factor in the results and a methodologi-
cal flaw to the study. This limitation has been
highlighted above when unrepresentative sam-
ple sizes were obtained making the strength
and presence of correlations difficult to establish
and resulted in the data presented largely as fre-
quencies in the results section of this study as
this was deemed the more representative
option.
The sensitivity of the HAD scale is largely
determined by the cut-off point chosen by the
researcher.41 However, the cut off point of 11
used in this study has been extensively utilised
by other researchers using the HAD scale and
is the traditional cut-off score achieving
7095% sensitivity and an 83% reliability.42
Patients who scored above 8 were also noted
as this increases the sensitivity of the scale to
81þ%.41 Overall, the HAD screening tool is a
reliable measure of anxiety and depression
among cancer patients with good internal con-
sistency.43
CONCLUSION
The research confirmed the under-diagnosis of
anxiety and depression within cancer patients
in their first 2 weeks of a radical course of radio-
therapy. It also identified specific patient char-
acteristics which make them more at risk of
developing these psychiatric disorders—breast
diagnosis, adjuvant chemotherapy regimes,
pain and age range 4050 years. Pain, in parti-
cular, was found to be a significant precursor to
the development of such disorders. However, as
with all psychological research, extraneous vari-
ables can impact heavily on the findings as they
prove difficult for the researcher to identify and
thus control.
The study can be considered a pilot on which
to base future research as it has identified many
areas which require further study. Further large-
scale research with similar aims and objectives
would be necessary to confirm the findings of
this small-scale research and their subsequent
generalisability, particularly the findings sug-
gesting that patients with cancer of the cervix
and head and neck may also be at high risk of
developing psychological dysfunction. Overall,
the results highlight the efficacy of psychiatric
screening and its urgent utility required. This
identification can be used to facilitate future
screening for these patients.
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